Pharma Exclusives Pressreleases
AbbVie Completes Acquisition of Capstan Therapeutics
Tuesday, August 19, 2025AbbVieannounced today that it has completed its acquisition of Capstan Therapeutics With the completion of the acquisition Capstan is now a part of AbbVie
Ifinatamab Deruxtecan Granted Breakthrough Therapy Designation by U.S. FDA for Patients with Pretreated Extensive-Stage Small Cell Lung Cancer
Monday, August 18, 2025Ifinatamab deruxtecan IDXd has been granted Breakthrough Therapy Designation BTD by the US Food and Drug Administration FDA for the treatment of adult patients with extensivestage small
Tonix Pharmaceuticals Announces FDA Approval of Tonmya™ (cyclobenzaprine HCl sublingual tablets) for the Treatment of Fibromyalgia
Saturday, August 16, 2025Tonix Pharmaceuticals Holding Corp a fullyintegrated biotechnology company today announced that the US Food and Drug Administration FDA approved Tonmya cyclobenzaprine HCl sublingual tablets
AbbVie Announces $195 Million Investment to Expand Active Pharmaceutical Ingredient Manufacturing in the U.S.
Wednesday, August 13, 2025AbbVietoday announced a million investment in its North Chicago Illinois manufacturing plant to expand domestic active pharmaceutical ingredient API production in the US This expansion is part of AbbVies previously announced commitment to invest mor...
Cybin Receives European Approval for EMBRACE, a Multinational Phase 3 Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder
Thursday, August 07, 2025Cybin Inc a clinicalstage breakthrough neuropsychiatry company committed to advancing mental healthcare by developing new and innovative nextgeneration treatment options today announced that its Clinical Trial Application CTA
GRI Bio Reports 6-Week Interim Biomarker Data in Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”)
Friday, August 01, 2025GRI Bio Inca biotechnology company advancing an innovative pipeline of Natural Killer T NKT cell modulators for the treatment of inflammatory fibrotic and autoimmune diseases today reported interim week biomarker results
Bayer upgrades currency-adjusted sales and earnings guidance for 2025 and establishes additional provisions for litigation in the United States
Friday, August 01, 2025Ahead of the publication of its business results for the second quarter of on Wednesday August Bayer AG is providing an update on key financial figures Due to a betterthanexpected business performance
Early Alzheimer’s Patients Continue to Benefit from Four Years of LEQEMBI® (lecanemab-irmb) Therapy New Clinical Data Presented at AAIC
Wednesday, July 30, 2025Eisai Co Ltd and Biogen Incannounced today that the latest findings demonstrating the benefits of continuous treatment with lecanemabirmb US brand name LEQEMBI an antiamyloid beta A protofibril
EMA Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Authorization of Moderna's COVID-19 mRNA Vaccine Targeting the SARS-CoV-2 Variant LP.8.1
Monday, July 28, 2025Moderna Inctoday announced that the European Medicines Agencys EMA Committee for Medicinal Products for Human Use CHMP has adopted a positive opinion recommending marketing authorization for an updated formulation
Imfinzi granted Priority Review and Breakthrough Therapy Designation in the US for patients with resectable early-stage gastric and gastroesophageal junction cancers
Monday, July 28, 2025AstraZenecas supplemental Biologics License Application sBLA for Imfinzi durvalumab has been accepted and granted Priority Review in the US for the treatment of patients with resectable earlystage and locally advanced
